Zuzana Tóthová (Author), Jana Tomc (Author), Nataša Debeljak (Author), Peter Solár (Author)

Abstract

Erythropoietin (EPO) acts on multiple tissues through its receptor EPOR, a member of a cytokine class I receptor superfamily with pleiotropic effects. The interaction of EPO and EPOR triggers the activation of several signaling pathways that induce erythropoiesis, including JAK2/STAT5, PI3K/AKT, and MAPK. The canonical EPOR/JAK2/STAT5 pathway is a known regulator of differentiation, proliferation, and cell survival of erythroid progenitors. In addition, its role in the protection of other cells, including cancer cells, is under intense investigation. The involvement of EPOR/JAK2/STAT5 in other processes such as mRNA splicing, cytoskeleton reorganization, and cell metabolism has been recently described. The transcriptomics, proteomics, and epigenetic studies reviewed in this article provide a detailed understanding of EPO signalization. Advances in this area of research may be useful for improving the efficacy of EPO therapy in hematologic disorders, as well as in cancer treatment.

Keywords

STAT5;erythropoietin receptor;molecular mechanisms;

Data

Language: English
Year of publishing:
Typology: 1.02 - Review Article
Organization: UL MF - Faculty of Medicine
UDC: 61
COBISS: 70001667 Link will open in a new window
ISSN: 1422-0067
Views: 237
Downloads: 41
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: STAT5;eritropoetinski receptor;molekularni mehanizmi;
Type (COBISS): Article
Pages: str. 1-13
Volume: ǂVol. ǂ22
Issue: ǂiss. ǂ13
Chronology: Jun. 2021
DOI: 10.3390/ijms22137109
ID: 14889988